Pirfenidone Versus Placebo As Prophylaxis Against Acute Radiation-induced Lung Injury Following Hypofractionated Radiotherapy in Breast Cancer Patients (PRILI): a Phase 2 Randomized, Double-Blind, Placebo-Controlled Study Evaluating
Latest Information Update: 04 Mar 2025
At a glance
- Drugs Pirfenidone (Primary)
- Indications Lung injury
- Focus Therapeutic Use
- Acronyms PRILI
Most Recent Events
- 26 Feb 2025 Planned End Date changed from 31 May 2024 to 31 May 2026.
- 26 Feb 2025 Planned primary completion date changed from 31 Jan 2024 to 31 Dec 2025.
- 02 Feb 2023 New trial record